Ask the Experts: Beyond the Basics in Managing Insulin and Other Antihyperglycemic Therapies for Type 2 Diabetes
Activity Overview
Please read the following information about this continuing education (CE) activity before accessing the presentation using link located at the bottom of this page.
Release Date: May 15, 2017
Expiration Date: May 15, 2018
Activity Type: Application-based
CE Credits: 1 hour (0.1 CEU), no partial credit
Activity Fee: Free of charge
Accreditation for Pharmacists
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Target Audience
This continuing pharmacy education activity was planned to meet the needs of pharmacists with an interest in diabetes management and new drug therapies who practice in hospitals, ambulatory care clinics, specialty pharmacies, and community pharmacies.
Activity Content
In this activity, the faculty uses clinical case vignettes to address advanced challenges related to the use of insulin and other antihyperglycemic agents in the management of type 2 diabetes, such as the influence of comorbidities. The content for this activity was based on questions and comments from participants at a recent educational symposium on this topic.
Learning Objectives
After the conclusion of this application-based educational activity, participants should be able to- Summarize key challenges related to the use of insulin and other antihyperglycemic agents in patients with type 2 diabetes with a high burden of comorbidities.
- Apply strategies to improve glycemic management in patients with type 2 diabetes.
Faculty
Curtis L. Triplitt, Pharm.D., CDCES, FADCES
Clinical Associate Professor, Medicine/Diabetes
University of Texas Health Science Center at San Antonio
Associate Director, Diabetes Research
Texas Diabetes Institute, University Health System
San Antonio, Texas
Curtis L. Triplitt, Pharm.D., CDCES, FADCES, is Clinical Associate Professor of Medicine, Division of Diabetes and Clinical Assistant Professor of Pharmacy at the University of Texas Health Science Center at San Antonio. Dr. Triplitt practices at the Texas Diabetes Institute, where he manages patients with an endocrinologist and is involved with diabetes and metabolism research.
Dr. Triplitt received his Doctor of Pharmacy degree from the University of Texas Health Science Center at San Antonio and the University of Texas at Austin. He completed an ASHP-accredited primary-care residency at the William S. Middleton Memorial Veterans Hospital in Madison, Wisconsin.
Dr. Triplitt is the Editor-in-Chief of Diabetes Spectrum and past Vice-Chair of the Texas Diabetes Council, Texas Department of State Health Services. He has served as an investigator on multiple clinical trials focusing on type 2 diabetes, including the effects of medications on insulin sensitivity, glycemic control, and hypertension, and he has published over 50 peer-reviewed articles and 10 book chapters on diabetes. In 2008 he was honored as Pharmacy Preceptor of the Year for the University of Texas. Dr. Triplitt lectures at both the national and statewide levels concerning diabetes and has been involved with the development of multiple clinical treatment algorithms for the prevention and treatment of diabetes in the State of Texas.
Joshua J. Neumiller, Pharm.D., CDE, FASCP
Vice Chair and Associate Professor
Department of Pharmacotherapy
Washington State University College of Pharmacy
Spokane, Washington
Joshua J. Neumiller, Pharm.D., CDE, FASCP, is Vice Chair and Associate Professor in the Department of Pharmacotherapy at Washington State University College of Pharmacy in Spokane, Washington.
Dr. Neumiller earned a Bachelor of Science degree in general science and a Doctor of Pharmacy degree from Washington State University in Spokane, Washington. He is a certified diabetes educator (CDE) and a fellow of the American Society of Consultant Pharmacists (ASCP).
Dr. Neumiller’s research interests involve the management of diabetes and prevention of adverse drug events during transitions in care. He is Editor-in-Chief for Diabetes Spectrum, a journal of the American Diabetes Association (ADA). He also is a contributing author for the ADA books, Medications for the Treatment of Diabetes, Practical Insulin, and American Diabetes Association Guide to Nutrition Therapy for Diabetes.
Dr. Neumiller is a member of ADA, ASCP, American Association of Diabetes Educators, American Pharmacists Association, and Washington State Pharmacy Association. He was recently awarded the 2016 Albert B. Prescott Pharmacy Leadership Award from the Pharmacy Leadership and Education Institute.
Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Guidelines for Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g., employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on presentations.
All faculty and planners for ASHP Advantage education activities are qualified and selected by ASHP Advantage and required to disclose any relevant financial relationships with commercial interests. ASHP Advantage identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity.
- Curtis L. Triplitt, Pharm.D., CDE, declares that he has served on the speakers bureau for AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., and Janssen Pharmaceuticals, Inc. He has also served as a consultant for AstraZeneca and Sanofi.
- Joshua J. Neumiller, Pharm.D., CDE, FASCP, declares that he has served as a consultant for Eli Lilly and Sanofi and on a speakers bureau for Novo Nordisk Inc. He has also received research grants from AstraZeneca, Johnson & Johnson, and Novo Nordisk Inc.
- All other planners report no financial relationships relevant to this activity.
Methods and CE Requirements
This is an online activity consisting of audio and slides, an assessment, and a course evaluation. Participants should claim CE credit for this home-study educational activity only if they have not claimed credit for the live activity. Participants must view the entire presentation, take the activity assessment (a minimum score of 70% is required), and complete the course evaluation to receive CE credit. The handout includes slides and the assessment for your reference.
To access the activity, click "Launch Presentation" below. On the last slide of the presentation you must click the “Close Activity and Process CE” button to link to ASHP’s elearning portal to complete the process for obtaining credit. Per ACPE, CPE credit must be claimed no later than 60 days from the date of the live activity or completion of a home-study activity. CPE credit will be reported directly to CPE Monitor.
Agenda
Ask the Experts: Beyond the Basics in Managing Insulin and Other Antihyperglycemic Therapies for Type 2 Diabetes
Curtis L. Triplitt, Pharm.D., CDE, and Joshua J. Neumiller, Pharm.D., CDE, FASCP
Faculty Discussion and Audience Questions (optional)
Launch Presentation (60 minutes)*
*Allow additional time to complete the assessment and evaluation.
